Evaluation of MicroRNAs and Vitamin B12 Expression in Subjects with Neurologic Symptoms of Depression, Anxiety and Fatigue in Long COVID-19

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06864156

Enrollment

Registered

2025-03-07

Start date

2025-02-18

Completion date

2025-07-31

Last updated

2025-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Long COVID, Long COVID Syndrome

Keywords

anxiety, depression, fatigue, microRNAs, vitamin b12, long covid

Brief summary

At the moment, the number of people with long COVID is unkown because there is still no effective diagnosis. This is why is very important to analyze the most common symptoms, which are: depression, anxiety and fatigue. This project seeks to analyze some blood components of people with long COVID, such as microRNAs and vitamin B12, in order to identify the body processes that changed after COVID-19 and thereby design better therapies and diagnostic methods focused on each of them. The hypothesis is that the expression of miR-21, -146a and -155 will be overexpressed as well as there will be a deficiency of vitamin B12 in serum in subjects suffering from long COVID with neurological symptoms of depression, anxiety and fatigue.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Subjects with confirmed diagnosis of COVID-19 by SARS-CoV-2 infection by PCR or antigen testing. * With presence of neurological symptoms of depression, anxiety and fatigue associated with COVID-19 after three months from the first day of acute infection symptoms.

Exclusion criteria

* Subjects who have presented symptoms of acute infection in the last twelve weeks. * Subjects who present diagnostic premorbid neurological alterations. * Subjects who do not have at least 2 doses of COVID-19 vaccine, with last application date equal or older than 3 months.

Design outcomes

Primary

Measure	Time frame
Change of microRNA expression between long COVID group and control group	immediately after the blood extraction
Change of vitamin B12 concentration between long COVID group and control group	immediately after the blood extraction
Link the expression of microRNAs with the score obtained in the instruments to evaluate depression, anxiety and fatigue	immediately after the blood extraction
Link the concentration of vitamin B23 with the score obtained in the instruments to evaluate depression, anxiety and fatigue.	immediately after the blood extraction

Countries

Mexico

Outcome results